BE2015C069I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C069I2
BE2015C069I2 BE2015C069C BE2015C069C BE2015C069I2 BE 2015C069 I2 BE2015C069 I2 BE 2015C069I2 BE 2015C069 C BE2015C069 C BE 2015C069C BE 2015C069 C BE2015C069 C BE 2015C069C BE 2015C069 I2 BE2015C069 I2 BE 2015C069I2
Authority
BE
Belgium
Application number
BE2015C069C
Other languages
French (fr)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BE2015C069I2 publication Critical patent/BE2015C069I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2015C069C 2002-12-20 2015-12-09 BE2015C069I2 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
BE2015C069I2 true BE2015C069I2 (cg-RX-API-DMAC7.html) 2024-08-08

Family

ID=32685362

Family Applications (3)

Application Number Title Priority Date Filing Date
BE2015C068C BE2015C068I2 (cg-RX-API-DMAC7.html) 2002-12-20 2015-12-09
BE2015C069C BE2015C069I2 (cg-RX-API-DMAC7.html) 2002-12-20 2015-12-09
BE2015C067C BE2015C067I2 (cg-RX-API-DMAC7.html) 2002-12-20 2015-12-09

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2015C068C BE2015C068I2 (cg-RX-API-DMAC7.html) 2002-12-20 2015-12-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE2015C067C BE2015C067I2 (cg-RX-API-DMAC7.html) 2002-12-20 2015-12-09

Country Status (28)

Country Link
US (2) US20060251676A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572233B1 (cg-RX-API-DMAC7.html)
JP (1) JP5475939B2 (cg-RX-API-DMAC7.html)
KR (3) KR101361769B1 (cg-RX-API-DMAC7.html)
AP (1) AP2005003347A0 (cg-RX-API-DMAC7.html)
AR (1) AR042530A1 (cg-RX-API-DMAC7.html)
AT (1) ATE503492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003293942B2 (cg-RX-API-DMAC7.html)
BE (3) BE2015C068I2 (cg-RX-API-DMAC7.html)
BR (1) BR0317544A (cg-RX-API-DMAC7.html)
CA (1) CA2510457C (cg-RX-API-DMAC7.html)
CY (1) CY1111552T1 (cg-RX-API-DMAC7.html)
DE (1) DE60336581D1 (cg-RX-API-DMAC7.html)
DK (1) DK1572233T3 (cg-RX-API-DMAC7.html)
EA (2) EA200701633A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055869A (cg-RX-API-DMAC7.html)
IL (1) IL169085A (cg-RX-API-DMAC7.html)
IS (1) IS2811B (cg-RX-API-DMAC7.html)
MA (1) MA27581A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006764A (cg-RX-API-DMAC7.html)
MY (1) MY144492A (cg-RX-API-DMAC7.html)
NO (1) NO20052846L (cg-RX-API-DMAC7.html)
NZ (1) NZ540811A (cg-RX-API-DMAC7.html)
OA (1) OA13147A (cg-RX-API-DMAC7.html)
PL (1) PL215257B1 (cg-RX-API-DMAC7.html)
PT (1) PT1572233E (cg-RX-API-DMAC7.html)
TW (1) TWI349557B (cg-RX-API-DMAC7.html)
WO (1) WO2004056389A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
AU2006239471A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2010099580A1 (en) * 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2015114506A2 (en) 2014-01-31 2015-08-06 Marini Bruna Biosensor for the determination of infections and associated pathologies
SG11201703262UA (en) 2014-10-24 2017-05-30 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
AU2016273638B2 (en) * 2015-06-02 2019-06-06 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
US11771754B2 (en) * 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
EP1572233A1 (en) 2005-09-14
BE2015C067I2 (cg-RX-API-DMAC7.html) 2024-08-08
TWI349557B (en) 2011-10-01
MA27581A1 (fr) 2005-10-03
KR101361769B1 (ko) 2014-02-10
IL169085A0 (en) 2007-07-04
IS2811B (is) 2012-11-15
EA200500834A1 (ru) 2006-02-24
ECSP055869A (es) 2005-09-20
US20050287161A1 (en) 2005-12-29
OA13147A (en) 2006-12-13
NO20052846L (no) 2005-07-13
KR20120123616A (ko) 2012-11-08
DK1572233T3 (da) 2011-06-27
WO2004056389A1 (en) 2004-07-08
IL169085A (en) 2014-04-30
MXPA05006764A (es) 2005-09-08
KR20120118087A (ko) 2012-10-25
EP1572233B1 (en) 2011-03-30
NZ540811A (en) 2007-03-30
DE60336581D1 (de) 2011-05-12
KR20050086924A (ko) 2005-08-30
IS7885A (is) 2005-06-09
AP2005003347A0 (en) 2005-06-30
MY144492A (en) 2011-09-30
CA2510457A1 (en) 2004-07-08
JP2006512413A (ja) 2006-04-13
BR0317544A (pt) 2005-11-22
EA200701633A1 (ru) 2007-12-28
BE2015C068I2 (cg-RX-API-DMAC7.html) 2024-08-08
AU2003293942B2 (en) 2009-12-10
JP5475939B2 (ja) 2014-04-16
PL377710A1 (pl) 2006-02-06
PT1572233E (pt) 2011-06-07
EA009179B1 (ru) 2007-12-28
PL215257B1 (pl) 2013-11-29
ATE503492T1 (de) 2011-04-15
CA2510457C (en) 2011-12-06
AR042530A1 (es) 2005-06-22
HK1085378A1 (en) 2006-08-25
US20060251676A1 (en) 2006-11-09
AU2003293942A1 (en) 2004-07-14
CY1111552T1 (el) 2015-08-05
TW200423957A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
BE2019C547I2 (cg-RX-API-DMAC7.html)
BE2019C510I2 (cg-RX-API-DMAC7.html)
BE2018C021I2 (cg-RX-API-DMAC7.html)
BE2017C049I2 (cg-RX-API-DMAC7.html)
BE2017C005I2 (cg-RX-API-DMAC7.html)
BE2016C069I2 (cg-RX-API-DMAC7.html)
BE2016C040I2 (cg-RX-API-DMAC7.html)
BE2016C013I2 (cg-RX-API-DMAC7.html)
BE2015C078I2 (cg-RX-API-DMAC7.html)
BE2018C018I2 (cg-RX-API-DMAC7.html)
BE2015C017I2 (cg-RX-API-DMAC7.html)
BE2014C051I2 (cg-RX-API-DMAC7.html)
BE2014C041I2 (cg-RX-API-DMAC7.html)
BE2014C030I2 (cg-RX-API-DMAC7.html)
BE2014C016I2 (cg-RX-API-DMAC7.html)
BE2014C015I2 (cg-RX-API-DMAC7.html)
BE2013C063I2 (cg-RX-API-DMAC7.html)
BE2013C039I2 (cg-RX-API-DMAC7.html)
BE2011C038I2 (cg-RX-API-DMAC7.html)
JP2003024451A5 (cg-RX-API-DMAC7.html)
JP2003186564A5 (cg-RX-API-DMAC7.html)
JP2003202952A5 (cg-RX-API-DMAC7.html)
JP2003202501A5 (cg-RX-API-DMAC7.html)
IN2004CH02744A (cg-RX-API-DMAC7.html)
BE2015C069I2 (cg-RX-API-DMAC7.html)